Skip to the stories
Saturday, 21 November 2026
Saved

Next edition

13:07

Headlines

Top Stories

United Therapeutics performs first UThymoKidney transplant in EXTEND trial

Researchers have transplanted a gene-edited pig kidney into a human patient with end-stage renal disease as part of a new clinical trial.

FTMQ Health, written by our newsroom0 views

Share

United Therapeutics and NYU Langone Health have transplanted the first investigational UThymoKidney into a human patient, BioBuzz reported. StreetInsider and MarketScreener both report that the procedure was performed as part of the company's EXTEND clinical trial for individuals suffering from end-stage renal disease. [1][6][7]

BioBuzz reported that the Durham, North Carolina-based company is evaluating a xenokidney derived from a gene-edited pig. The organ is specifically designed to train the recipient's immune system to accept the transplanted tissue. [1]

Other North Carolina life sciences companies are also moving clinical programs forward, according to BioBuzz. Dignify Therapeutics, located in Research Triangle Park, has dosed the first healthy subject in a Phase 1 clinical trial evaluating DTI-117 for neurogenic bowel dysfunction, with initial trial data anticipated in 2027. [1]

Separate medical advances were reported across the pharmaceutical sector. Sleep Review reported that Pfizer and Blackstone Life Sciences signed a 1.5 billion dollar strategic funding agreement to support clinical development through 2028 of berobenatide, an investigational monthly GLP-1 injection being evaluated in Phase 3 trials for chronic weight management, obesity, and obstructive sleep apnea. [3]

Share

In short

  • United Therapeutics and NYU Langone Health transplanted the first investigational UThymoKidney in the EXTEND trial.
  • The trial evaluates a xenokidney derived from a gene-edited pig for patients with end-stage renal disease.
  • Dignify Therapeutics dosed its first healthy participant in a Phase 1 trial of DTI-117 for neurogenic bowel dysfunction.
  • Pfizer and Blackstone Life Sciences entered a 1.5 billion dollar agreement to fund a monthly GLP-1 injection trial.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]NC Life Sciences News: United Therapeutics’ EXTEND Trial, Vogenx Russell Listing & MoreBioBuzz, 19h ago (the report this story comes from)
  2. [2]United Therapeutics Corporation Announces First Transplant in EXTEND Clinical Trial of UThymoKidney™ in Patients with End-Stage Renal DiseaseUnited Therapeutics Investor Relations, 1d ago
  3. [3]Pfizer, Blackstone Life Sciences Enter Strategic Funding Agreement for GLP-1Sleep Review, 20h ago
  4. [4]Next-Gen Journal Leaders, What “Healthy” Means, Shelf Life Signals, and More NewsIFT.org, 1d ago
  5. [5]U.S. Clinical Trial Data Annotation Services Market Is Going to Boom |• Medidata Solutions • Oracle Health SciencesopenPR.com, 1d ago
  6. [6]United Therapeutics Corporation Announces First Clinical Xenotransplant in Extend Study of Uthymokidney in Patients with End-Stage Renal Diseasemarketscreener.com, 1d ago
  7. [7]United Therapeutics performs first pig kidney-thymus transplant in EXTEND trialStreetInsider, 1d ago
  8. [8]Arcera Life Sciences and Innogen Pharmaceuticals SignGlobeNewswire, 2d ago
  9. [9]United Therapeutics Completes First UThymoKidney Trial Transplantgrafa.com, 22h ago
  10. [10]United Therapeutics (UTHR) Completes First Clinical XenotransplaGuruFocus, 1d ago

Background

  1. [11]Museum of Life and Science on Wikipedia
  2. [12]Nektar Therapeutics on Wikipedia
  3. [13]FDA rejects Capricor Therapeutics Duchenne muscular dystrophy cell therapy FTMQ Health, 15h ago

Our newsroom writes these reports with the help of software, from the 13 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Top Stories

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.